News and Events
Stay up to date with news and events
Huntington’s disease therapeutics conference 2023 – Day 1
Hello from Dubrovnik, Croatia, where the 2023 CHDI Therapeutics Conference will be taking place from Monday, April 24th, through Thursday, April 27th! This conference is…
PROOF-HD study of pridopidine ends with negative result
Top line results of the PROOF-HD study, run by Prilenia Therapeutics and testing pridopidine, have been announced at the American Academy of Neurology convention. Sadly…
Astrocytes: The new star in HD research?
The most obvious changes related to Huntington’s disease (HD) happen to neurons, the nervous system’s messenger cells that send and receive information throughout the brain…
Hunting for balance: how the huntingtin protein compensates in HD
A group led by Dr. Sandrine Humbert from the French National Institute for Health and Medical Research published new work in the prestigious journal Science….
Roche Phase II GENERATION HD2 study underway
Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more…